Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 20/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459176 | 1.00 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566407 | 0.88 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462981 | 0.88 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462986 | 0.88 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12311126 | 0.87 | MTNR1A (0.64) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462815 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462813 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566259 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL4746147 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL6810066 | 0.81 | MTNR1A (0.79) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000746-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA PHARMACEUTICAL (JP) | 2016-01-07 | — | — | US | claimed |
| US-20150142085-A1 | Pharmaceutical Compositions and Methods for Treating Age-Related Macular Degeneration with Melatonin Analogues | TAKADA PHARMACEUTICALS U S A INC (US) | 2015-05-21 | — | — | US | claimed |
| EP-2369926-B1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA PHARMACEUTICAL (JP) | 2015-04-22 | — | — | EP | claimed |
| US-8785491-B2 | Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20110229464-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA GLOBAL RESEARCH CORPORATION | 2011-09-22 | — | — | US | claimed |
| US-20160000746-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA PHARMACEUTICAL (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150142085-A1 | Pharmaceutical Compositions and Methods for Treating Age-Related Macular Degeneration with Melatonin Analogues | TAKADA PHARMACEUTICALS U S A INC (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2369926-B1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA PHARMACEUTICAL (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8785491-B2 | Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110229464-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | TAKEDA GLOBAL RESEARCH CORPORATION | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229464-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | MTNR1A, MTNR1B, AGER | MTNR1A 1/4885MTNR1B 2/4885ABCB11 4447/4885 |
| US-20160000746-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES | MTNR1A, MTNR1B, AGER | MTNR1A 1/4885MTNR1B 2/4885ABCB11 4447/4885 |
| US-20150142085-A1 | Pharmaceutical Compositions and Methods for Treating Age-Related Macular Degeneration with Melatonin Analogues | MTNR1A, MTNR1B, AGER | MTNR1A 1/4885MTNR1B 2/4885ABCB11 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.